- Record: found
- Abstract: found
- Article: not found
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
Suzanne L Topalian
1 ,
Mario Sznol ,
David F McDermott ,
Harriet M Kluger ,
Richard D Carvajal ,
William H Sharfman ,
Julie R Brahmer ,
Donald P Lawrence ,
Michael B Atkins ,
John D Powderly ,
Philip D Leming ,
Evan J Lipson ,
Igor Puzanov ,
David C Smith ,
Janis M Taube ,
Jon M Wigginton ,
Georgia D Kollia ,
Ashok Gupta ,
Drew M Pardoll ,
Jeffrey A Sosman ,
F Stephen Hodi
Apr 01 2014
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Programmed cell death 1 (PD-1) is an inhibitory receptor expressed by activated T cells that downmodulates effector functions and limits the generation of immune memory. PD-1 blockade can mediate tumor regression in a substantial proportion of patients with melanoma, but it is not known whether this is associated with extended survival or maintenance of response after treatment is discontinued.